Novotech boosts global strength with two acquisitions

Singapore-based Novotech, the leading Asia-Pacific centered biotech contract research organization (CRO), has acquired EastHORN, a European CRO with clinical, medical and regulatory expertise in multiple strategically important locations across the continent.

The acquisition is part of Novotech’s global expansion program. It has already been collaborating for several years with EastHORN, which was established in 2004 and has over 250 employees.

The acquisition, financial terms of which are not disclosed, means biotech clients can access Novotech’s unique and unparalleled suite of early to late-phase CRO services across Europe and the USA, with a specialist focus on Asia Pacific where the company has built a reputation for delivering high-quality expedited clinical trials.